BioMarin Pharma Announces Board & Executive Changes
Ticker: BMRN · Form: 8-K · Filed: Aug 11, 2025 · CIK: 1048477
| Field | Detail |
|---|---|
| Company | Biomarin Pharmaceutical INC (BMRN) |
| Form Type | 8-K |
| Filed Date | Aug 11, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 B |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-compensation, board-of-directors
Related Tickers: BMRN
TL;DR
BioMarin's board and exec comp got a shake-up effective Aug 5.
AI Summary
BioMarin Pharmaceutical Inc. announced on August 5, 2025, changes in its board of directors and executive compensation. The filing details the departure of certain officers, the election of new directors, and updates to compensatory arrangements for key executives. These changes are effective as of August 5, 2025.
Why It Matters
Changes in a company's board and executive compensation can signal shifts in strategy, governance, or future performance expectations.
Risk Assessment
Risk Level: low — This filing reports routine corporate governance changes and does not indicate any immediate financial distress or significant operational risk.
Key Players & Entities
- BioMarin Pharmaceutical Inc. (company) — Registrant
- August 5, 2025 (date) — Effective date of reported changes
FAQ
What specific roles have seen departures or appointments?
The filing indicates the departure of certain officers and the election of new directors, along with changes to compensatory arrangements for certain officers, but does not specify the exact roles in this summary.
When were these changes effective?
The changes reported in this Form 8-K were effective as of August 5, 2025.
What is the primary purpose of this Form 8-K filing?
The primary purpose is to report current information about the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
Under which section of the Securities Exchange Act is this filing made?
This filing is made pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
Where is BioMarin Pharmaceutical Inc. headquartered?
BioMarin Pharmaceutical Inc.'s principal executive offices are located at 770 Lindaro Street, San Rafael, California 94901.
Filing Stats: 591 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2025-08-11 16:02:59
Key Financial Figures
- $0.001 B — ich registered Common Stock, par value $0.001 BMRN The Nasdaq Global Select Market In
Filing Documents
- bmrn-20250805.htm (8-K) — 22KB
- 0001048477-25-000098.txt ( ) — 135KB
- bmrn-20250805.xsd (EX-101.SCH) — 2KB
- bmrn-20250805_lab.xml (EX-101.LAB) — 21KB
- bmrn-20250805_pre.xml (EX-101.PRE) — 12KB
- bmrn-20250805_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. BioMarin Pharmaceutical Inc., a Delaware corporation Date: August 11, 2025 By: /s/ G. Eric Davis G. Eric Davis Executive Vice President, Chief Legal Officer